Predictive Diagnostics

Predictive Diagnostics was a molecular diagnostics company focused on the development of proteomic and genomic tests for the early detection of pregnancy-related complications. The company's primary focus was on identifying biomarkers associated with preterm birth, aiming to provide clinicians with actionable data to improve maternal and neonatal outcomes. Its core technology and intellectual property were centered on a proprietary proteomic platform designed to predict the risk of spontaneous preterm delivery. In 2011, the company was acquired by Sera Prognostics, which integrated Predictive Diagnostics' assets to further develop and commercialize the PreTRM test.